PEPTIDES for Veterans Act

Nancy Mace

Republican · SC · Representative

Source: Congress.gov · FEC

No cosponsors on record. Bills can pass without cosponsors — this often means the sponsor introduced the bill alone, either because it's a messaging bill, a chairman's mark, or simply early in the legislative cycle.

Referred to the House Committee on Veterans' Affairs.

2026-09-01

Source: Congress.gov

Plain-English summary pending. Introduced on 2026-09-01. Check back soon — summaries are generated as bills progress through Congress.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 10212 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 10212 To direct the Secretary of Veterans Affairs to study the potential benefits of peptide-based therapies for veterans receiving care through the Department of Veterans Affairs, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES September 1, 2026 Ms. Mace introduced the following bill; which was referred to the Committee on Veterans' Affairs _______________________________________________________________________ A BILL To direct the Secretary of Veterans Affairs to study the potential benefits of peptide-based therapies for veterans receiving care through the Department of Veterans Affairs, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act'' or the ``PEPTIDES for Veterans Act''. SEC. 2. REVIEW OF REGULATIONS AND GUIDANCE RELATING TO PEPTIDES. (a) Review Required.--The Secretary of Veterans Affairs shall conduct a review of the regulations and guidance relating to peptides and, in particular, the scope of ``peptide'' as a defined term in Federal regulations and guidance, and shall establish an appropriate definition of ``peptide'' for purposes of this Act. A primary focus of the review shall be to consider addressing developments in research relating to peptides, if any, since the regulations, guidance, and defined terms were established. (b) Report.--Not later than 180 days after the date of the enactment of this Act, the Secretary shall submit to Congress a report on the results of the review. The report shall-- (1) summarize the regulations, guidance, and defined terms; (2) describe the research developments, if any, since the regulations, guidance, and defined terms were established; (3) set forth the definition of ``peptide'' established by the Secretary for purposes of this Act; (4) set forth a definition of ``peptide-based therapy'' for purposes of this Act and any guidance the Secretary determines to be appropriate regarding what constitutes such a therapy; and (5) explain the rationale for the definition established by the Secretary and the differences, if any, between such definition and other definitions of ``peptide'' in Federal regulations and guidance. SEC. 3. STUDY ON POTENTIAL BENEFITS OF PEPTIDE-BASED THERAPIES FOR VETERANS AND PILOT PROGRAM TO EVALUATE THERAPIES. (a) Study Required.-- (1) In general.--Beginning on the date on which the report required by section 2 is submitted to Congress, the Secretary of Veterans Affairs shall carry out a study on the safety, efficacy, and potential therapeutic benefits of peptide-based therapies for veterans receiving care at medical facilities of the Department of Veterans Affairs. (2) Matters included.--In carrying out the study, the Secretary shall-- (A) review medical research; (B) establish clinical protocols; (C) identify potential applications relating to recovery, rehabilitation, chronic pain, mental health, physical wellness, and other service-connected conditions affecting veterans; and (D) consider the extent to which peptides are safe to use for clinical and rehabilitation purposes. (3) Completion of study.--The study shall be completed not later than the date that is 18 months after the date on which the report required by section 2 is submitted to Congress. (4) Report.--Upon completing the study, the Secretary shall submit to Congress a report on the results of the study. The report shall include findings, recommendations, and a determination as to whether peptide-based therapies should be made available to veterans receiving care at medical facilities of the Department of Veterans Affairs. (b) Pilot Program.-- (1) In general.--If the Secretary determines, in the report required by subsection (a)(4), that…

peptide-based therapies should be provided to such veterans, then the Secretary shall carry out a pilot program under which peptide-based therapies are made available to such veterans and the results of those therapies are assessed. (2) Limitations on pilot program.--Participation in the pilot program shall be limited to veterans who elect to participate, and the Secretary shall impose such other geographic, clinical, or other limitations on the pilot program as the Secretary considers appropriate. (3) Completion of pilot program.--The pilot program shall be completed not later than the date that is 5 years after the date on which it is established. (4) Report.--Upon completing the pilot program, the Secretary shall submit to Congress a report on the results of the pilot program. The report shall include-- (A) a detailed description of the effectiveness of peptide treatments for clinical and rehabilitation purposes, including a determination as to what conditions or ailments are improved by use of peptides; (B) guidance on large-scale implementation of peptides throughout the medical facilities of the Department; and (C) any challenges encountered in carrying out the pilot program. <all>

• HR10145SOUND Pesticide Research Act
  Referred to Committee · 2026-08-24
• HR10144Pesticide Harm Accountability Act
  Referred to Committee · 2026-08-24
• HR10127TRANS Government Research Act
  Referred to Committee · 2026-08-20
• HR10098Restoring the Death Penalty in DC Act
  Referred to Committee · 2026-08-13